ResMed (RMD)
(Delayed Data from NYSE)
$244.28 USD
+1.81 (0.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$244.28 USD
+1.81 (0.75%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Zacks News
NUVA vs. RMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NUVA vs. RMD: Which Stock Is the Better Value Option?
Should iShares Morningstar MidCap Growth ETF (IMCG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCG
ResMed (RMD) Inks Deal to Acquire MEDIFOX DAN in Germany
by Zacks Equity Research
ResMed's (RMD) acquisition of a renowned out-of-hospital software solutions company is expected to strengthen its SaaS business.
Phibro (PAHC) Up 7.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ResMed (RMD) Q3 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.
ResMed (RMD) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of -8.33% and 4.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More
by Urmimala Biswas
Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.
Should iShares Morningstar MidCap Growth ETF (IMCG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IMCG
Here's Why You Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
ResMed's (RMD) robust international performance and an ongoing rebound in device sales instill investor confidence in the stock.
ResMed's (RMD) SaaS Arm Strength Aids Growth, Supply Woes Stay
by Zacks Equity Research
ResMed's (RMD) growing focus to expand in the high-growth international markets is an added upside.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) on increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts.
ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates
by Zacks Equity Research
ResMed's (RMD) Q2 earnings meet estimates, with robust demand for sleep and respiratory care devices driving the top line.
ResMed (RMD) Q2 Earnings Meet Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 0% and 3.92%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for ResMed (RMD) This Earnings Season?
by Zacks Equity Research
ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down 9.2% in 4 Weeks, Here's Why You Should You Buy the Dip in ResMed (RMD)
by Zacks Equity Research
The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Walgreens Boots (WBA) Q1 Earnings Top Estimates, 2022 View Up
by Zacks Equity Research
Walgreens Boots' (WBA) revenues increased year over year in the fiscal first quarter, driven by COVID-19 vaccinations and testing.
Why ResMed (RMD) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) strong sales in its mask product offering and growing uptake of its digital health solutions.
ABT or RMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ABT vs. RMD: Which Stock Is the Better Value Option?
Here's Why You Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
ResMed (RMD) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
ResMed (RMD) reports better-than-expected earnings and revenues with robust demand for sleep and respiratory care devices driving Q1 top line.
ResMed (RMD) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 11.85% and 5.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?